Cassava Sciences Inc (SAVA)
12.33
-6.62
(-34.92%)
USD |
NASDAQ |
Jun 28, 16:00
13.49
+1.16
(+9.38%)
After-Hours: 20:00
Cassava Sciences SG&A Expense (TTM): 15.84M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 15.84M |
December 31, 2023 | 16.53M |
September 30, 2023 | 15.76M |
June 30, 2023 | 14.30M |
March 31, 2023 | 13.46M |
December 31, 2022 | 11.99M |
September 30, 2022 | 12.80M |
June 30, 2022 | 11.70M |
March 31, 2022 | 9.966M |
December 31, 2021 | 8.055M |
September 30, 2021 | 5.058M |
June 30, 2021 | 4.384M |
March 31, 2021 | 3.965M |
December 31, 2020 | 3.739M |
September 30, 2020 | 3.472M |
June 30, 2020 | 3.265M |
March 31, 2020 | 3.292M |
December 31, 2019 | 3.391M |
September 30, 2019 | 3.301M |
June 30, 2019 | 3.318M |
March 31, 2019 | 3.471M |
December 31, 2018 | 3.693M |
September 30, 2018 | 3.824M |
June 30, 2018 | 3.953M |
March 31, 2018 | 4.058M |
Date | Value |
---|---|
December 31, 2017 | 4.335M |
September 30, 2017 | 4.664M |
June 30, 2017 | 4.571M |
March 31, 2017 | 4.923M |
December 31, 2016 | 5.781M |
September 30, 2016 | 5.487M |
June 30, 2016 | 5.933M |
March 31, 2016 | 5.879M |
December 31, 2015 | 5.102M |
September 30, 2015 | 5.247M |
June 30, 2015 | 5.346M |
March 31, 2015 | 5.267M |
December 31, 2014 | 5.127M |
September 30, 2014 | 5.258M |
June 30, 2014 | 5.119M |
March 31, 2014 | 4.936M |
December 31, 2013 | 4.837M |
September 30, 2013 | 5.854M |
June 30, 2013 | 6.565M |
March 31, 2013 | 6.887M |
December 31, 2012 | 7.181M |
September 30, 2012 | 6.594M |
June 30, 2012 | 6.346M |
March 31, 2012 | 6.673M |
December 31, 2011 | 6.698M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
3.265M
Minimum
Jun 2020
16.53M
Maximum
Dec 2023
8.380M
Average
6.556M
Median
SG&A Expense (TTM) Benchmarks
ACADIA Pharmaceuticals Inc | 413.31M |
Vertex Pharmaceuticals Inc | 1.238B |
Cormedix Inc | 43.24M |
Regulus Therapeutics Inc | 10.30M |
Oragenics Inc | 5.999M |